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reviewers independently selected trials, assessed their quality and extracted data. 
Meta-analysis of head-to-head trials was performed. RESULTS: Seven RCTs compar-
ing CIC vs. BUD were identiﬁ ed and included in the analysis. Comparisons of both 
interventions in 1:1 and 1:2 dose ratios were assessed in 3 and 4 trials, respectively. 
CIC as compared with BUD in 1:1 dose ratio was associated with signiﬁ cant improve-
ment in forced vital capacity (FVC) and peak expiratory ﬂ ow (PEF) by spirometry 
(WMD = 0.09 [0.03; 0.14] and WMD = 19.00 [2.37; 35.63], respectively) as well as 
reduction in proportion of symptom-free days (p = 0.018). No statistically signiﬁ cant 
differences between both drugs in 1:2 dose ratios were observed. CIC and BUD in 
either dose showed comparable efﬁ cacy with respect to the risk of asthma exacerba-
tion, improvement in symptoms of asthma and forced expiratory volume in 1 second 
(FEV1). CIC-treated patients experienced less upper respiratory tract infections than 
those treated with BUD in 1:1 dose ratio, however the difference was on the border 
of statistical signiﬁ cance (RR = 0.65 [0.43; 0.99], NNT not signiﬁ cant). There were 
no statistically signiﬁ cant differences between CIC and BUD in either dose ratio with 
respect to risk of adverse events, adverse events related to study medication, pharyn-
gitis and dysphonia. CONCLUSIONS: Ciclesonide provides an improvement in spi-
rometric paramethers and reduction of asthma symptom-free days as compared to 
budesonide in 1:1 dose ratio, while no differences were noticed between CIC and BUD 
in 1:2 dose ratio. Safety proﬁ le of ciclesonide seems to be comparable with budesonide.
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OBJECTIVES: Current asthma management recommendations are based on the level 
of asthma control rather than disease severity. The ﬁ nancial impact associated with 
asthma control needs to be determined. The primary objective of this study was to 
estimate quality of life and health care costs according to the patients’ level of asthma 
control in France and in Spain. METHODS: An observational retrospective bottom-up 
cost of illness study was conducted in adults patients with asthma. Investigators were 
general practitioners. Asthma control was evaluated using the validated auto-test 
Asthma Control Test (ACTTM) for a one month period and 2009 GINA’s asthma 
control criteria for a three months period. Quality of life (QoL) was assessed using 
EQ-5D proﬁ le. Costs (direct and indirect) were evaluated from a societal perspective. 
RESULTS: 794 patients (France: 391; Spain: 403) were enrolled in the ﬁ rst quarterly 
wave of the survey. Based on the ACT, asthma was determined to be well-controlled 
(ACT ≥ 20) in 48.1% [IC 95%: 42.1%–54%] and 56.2% [IC95: 51.1%–61.2%] of 
French and Spanish patients respectively. In both countries, EQ-5D scores were 0.9 
and 0.7 in well-controlled and not well-controlled patients respectively (P < 0.0001). 
Total costs of asthma were directly related to asthma control in both countries. The 
average cost (Euros/month/patient) of well-controlled asthma was c28 (±36) in France 
and c77 (±105) in Spain compared with c140 (±782) (p = 0.0009) and c252 (±380) 
(p < 0.0001) respectively for not well-controlled asthma. Similar associations were 
observed using the latest GINA’s criteria. CONCLUSIONS: We found strong associa-
tions between asthma control level, costs and QoL in patients with asthma. Achieve-
ment of good clinical control of asthma may result in a signiﬁ cant decrease of the 
economic burden of asthma and a better health status in adults.
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OBJECTIVES: The prevalence of asthma has been reported to be increasing for 
decades, but recent studies suggest a leveling off or even decrease in prevalence among 
children. The objective of this study was to assess the trends in anti-asthma medication 
use in Dutch children from 1998 until 2007. METHODS: From the PHARMO Record 
Linkage System, an administrative database network of outpatient pharmacies, hos-
pitals, and other settings, including data of ~4 million individuals in deﬁ ned areas of 
the The Netherlands, we assessed 1) the proportion of children aged 0–19 years with 
at least one dispensing for short (SABA) or long-acting β2-antagonists (LABA), inhaled 
glucocorticoids (ICS), ﬁ xed dose combinations (FDC) of LABA and ICS or leukotriene 
receptor antagonists (LRTA) in the years 1998–2007 stratiﬁ ed by age groups, 2) the 
proportion of users per type for each year and 3) the age distribution per medication 
type for the year 2007. RESULTS: Overall prevalence of anti-asthma medication use 
was approximately 7% and remained stable between 1998 and 2007. Prevalence was 
highest among children aged 0–1 years and declined with increasing age. Over time, 
the prevalence remained stable in all age groups, except for the youngest in which it 
increased from 10% in 1998 to 19% in 2007. Use of ICS and LABA declined over 
time (user proportions: −17% and −3%), against increased use of LABA-ICS FDC and 
LRTA (+15% and +3%). Children <6 years made up relatively large proportions of 
SABA and ICS users, while the older children were more dominant in the other medica-
tion types. CONCLUSIONS: This study provides a comprehensive overview of trends 
in anti-asthma medication use in children showing no overall change in prevalence 
over time. However, a change in type of medication was observed. 
RESPIRATORY-RELATED DISORDERS – Cost Studies
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OBJECTIVES: To compare the impact of different pharmacotherapies on the cost of 
exacerbation of COPD in public hospitals in Hong Kong. METHODS: This was a 
retrospective study comparing the cost of management of chronic obstructive pulmo-
nary disease (COPD) in patients from a public hospital perspective in Hong Kong. 
Institutional ethics approval was obtained. The patients were above 65 years with a 
diagnosis of COPD of stage 3 or above based on the GOLD guideline. COPD was 
deﬁ ned based on ICD-9-CM codes. Two cohorts of patients were included: 1) Those 
who received ﬂ uticasone propionate and salmeterol, plus ipratropium bromide and 
salbutamol inhalation, and 2) Those who received ipratropium bromide and salbuta-
mol, and beclomethasone inhalation. Patients were followed for 6 months before and 
after medications. The date one of the therapies started was the index date. RESULTS: 
A total of 75 patients were recruited over January to June 2008. All values are 
expressed as mean ± SD. The number of emergency room visits and cost of visits 
before and after the index date for both cohorts did not show a signiﬁ cant difference 
(1.86 ± 2.5 days vs. 1.62 ± 1.93 days and HKD1061 ± 1442 vs. HKD924 ± 1102 for 
cohort 1, 1.15 ± 1.28 days vs. 1.02 ± 1.29 days and HKD657 ± 730 vs. HKD582 ± 
735 for cohort 2, p > 0.1). There was a trend of reduction in hospitalization days and 
cost of stay before and after the index date for cohort 1 (although not reaching a 
signiﬁ cant level) but not in cohort 2 (20.6 ± 28.4 days vs. 15.6 ± 18.8 days and 
HKD68162 ± 93875 vs. HKD51662 ± 66278 for cohort 1, 11.1 ± 13.5 days vs. 10.2 
± 13.2 days and HKD36730 ± 44604 vs. HKD33860 ± 43571 for cohort 2, p > 0.1). 
CONCLUSIONS: A trend of reduction in hospital stay was demonstrated (although 
not statistically signiﬁ cant) in patients after receiving combination therapy of ﬂ utica-
sone propionate and salmeterol plus ipratropium bromide and salbutamol. This is 
consistent with earlier studies in other countries. a larger number of patients is 
required to prove the signiﬁ cance of this ﬁ nding.
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OBJECTIVES: To analyze the GP’s prescriptions of bronchodilators for managing the 
patients with stable COPD, to compare the prescriptions with Ukrainian National 
COPD Management Guidelines. And we estimated the annual costs for bronchodila-
tors were used most frequently. METHODS: The analysis of prescription habits based 
on data from outpatient personal medical cards of 103 patients with COPD (2nd 
Municipal Clinic, Bila Tserkva, Ukraine), focused on bronchodilators as central medi-
cations for symptomatic treatment. Among 103 patients 15 were with mild COPD, 
75 with moderate and 13 with severe (according to GOLD). The prescriptions for 
regular treatment were compared with national guidelines. Annual medications costs 
were calculated based on the number of medicines units for 24 hour bronchodilation 
during a year, multiplied by the one unit price in UAH (1 EUR = 10.05 UAH). 
RESULTS: Regular basis was prescribed to 87 patients. Among 87 prescriptions 
13.7% were long-acting inhaled bronchodilators or combinations, 86.3% were short-
acting inhaled bronchodilators, methylexanthines or combinations. Ranking to a 
number of medicines were most frequently prescribed: 56.8% ﬁ xed combination 
Ipratropium/Fenoterol, 10.2% Tiotropium, 9.1% Fenoterol, 7.9% Salbutamol. 
Annual costs for these bronchodilators were: 1206.0, 6262.0, 1303.0 and 275.0 UAH, 
respectively. CONCLUSIONS: The most frequently prescribed bronchodilator was 
Ipratropium/Fenoterol. It’s available during decades and inexpensively. But its basis 
requires triple daily medication, in consequence of that persistency rate might be 
reduced with effectiveness reducing, respectively. Tiotropium ranked second in the 
prescription frequency. It has duration of action of more than 24 hours, high effective-
ness and safety levels but gets 6262.0 UAH annually. So the affordability of a bron-
chodilator is weighty criterion for Ukrainian GP’s prescriptions. But medications costs 
must be scrupulously compared with effectiveness for their including to the national 
formulary and reimbursement decision-making.
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OBJECTIVES: The aim of this study is to analyze the economic impact of non-
adherence to GOLD guidelines in COPD patients. METHODS: A retrospective analy-
sis was carried out in a claim database. Patients ≥40 years-old with diagnosis of COPD 
conﬁ rmed with spirometry (FEV1/FVC < 0.7) were eligible for this analysis. Patients 
were classiﬁ ed into two groups according to whether they fulﬁ ll with therapeutics 
recommendations by severity deﬁ ned in GOLD guidelines (GOLD group) or those 
who don’t fulﬁ ll (NO-GOLD group). Demographics, medical and use of resources 
data were collected and direct and indirect costs were analyzed. a probabilistic mul-
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tivariate sensitivity analysis of avoided costs was carried out. All results are presented 
annualized and costs expressed in c2009. RESULTS: A total of 1365 patients were 
included, 79.5% males, mean (±SD) age was 71.4 (±10,3), mean FEV1 was 65.34% 
and a COPD history of 5.5 (±2,9) years. Patients were divided into GOLD group and 
NO-GOLD group and in stage II (FEV1 < 80% and ≥50%) and stage III (FEV1 < 50% 
and ≥30%) for both groups. Total annual costs per patient were analyzed. Directs 
costs analyzed were treatment, medical visits, emergency visits, hospital stay, labora-
tory, spirometry, radiology and oxigenotherapy. Indirect cost evaluated was sick leave. 
Avoided costs between both groups will be analyzed, and conﬁ rmed with sensitivity 
analysis. CONCLUSIONS: The results of this study will provide whether the adher-
ence to the recommendations of the GOLD guidelines in COPD patients can lead to 
signiﬁ cant savings to the Spanish health care system.
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OBJECTIVES: Persistent air leaks after lung resection surgery often lead to increased 
complications including longer length of hospital stay and resulting treatment costs. 
a PEG hydrogel sealant (PleuraSeal™) is used as an adjunct to standard closure of 
pleural air leaks during lung resection surgery and has demonstrated shorter hospital-
izations (1.7 fewer days; Wain JC et al, 2008, Conference Abstract) and more rapid 
removal of chest tubes in a clinical study (Covidien, data on ﬁ le) when compared with 
standard closure (e.g. staples and sutures alone). Our study was designed to estimate 
the potential cost offsets for using PleuraSeal™ compared with standard closure in 
100 hypothetical patients from a Spanish hospital who had an air leak after lung 
resection surgery using the cost offset from shorter hospital stays balanced against the 
cost for PleuraSeal™. METHODS: We assumed the cost for PleuraSeal™ in Spain to 
be c420 per treatment applied to all 100 hypothetical patients compared with no 
added cost for standard closure. We then balanced the added cost for PleuraSeal™ 
with the reduction in number of hospital days and subsequent costs (c590/day [Varela 
et al, 2006] @1.7 fewer days per patient) compared with standard closure and calcu-
lated the potential cost offset for PleuraSeal™. RESULTS: A Spanish hospital that 
performs 100 lung resections with air leaks can expect to save c58,300, or approxi-
mately c583 per patient when compared to standard closure as patients who had air 
leaks stayed in hospital an average of 1.7 days longer than those without air leaks. 
CONCLUSIONS: The cost for PleuraSeal™ is completely offset by the shorter length 
of hospital stay compared with standard closure inSpain. PleuraSeal™ is a compelling 
option for Spanish hospitals that perform lung resection surgeries as the cost of the 
treatment is completely offset by the reduction in air leaks and subsequent shorter 
hospital stay.
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OBJECTIVES: Persistent air leaks after lung resection surgery often lead to increased 
complications. a PEG hydrogel sealant (PleuraSeal™) is used as an adjunct to standard 
closure of pleural air leaks and has demonstrated shorter hospitalizations (1.7 fewer 
days; Wain JC et al, 2008, Conference Abstract) when compared with standard of 
care (e.g. staples and sutures alone). Our study was designed to estimate the potential 
cost offsets for using PleuraSeal™ in 100 hypothetical patients with an air leak using 
the cost offset from shorter hospital stays balanced against the cost for PleuraSeal™. 
METHODS: We assumed the cost for PleuraSeal™ in Italy to be c420 per treatment 
applied to all 100 hypothetical patients compared with no added cost for standard of 
care. We then balanced the cost for PleuraSeal™ with the reduction in hospital days 
and subsequent costs (c337/ thoracic ward day, a Brunelli et al, 2007), then calculated 
the potential cost offset for PleuraSeal™. RESULTS: An Italian hospital that performs 
100 lung resections with air leaks can expect to save c15,300, or approximately c153 
per patient when compared to standard of care as patients who had air leaks stayed 
in hospital an average of 1.7 days longer than those without air leaks. CONCLU-
SIONS: The cost for PleuraSeal™ is completely offset by the shorter length of hospital 
stay compared with standard of care in Italy. PleuraSeal™ is a compelling option for 
Italian hospitals that perform lung resection surgeries as the cost of the treatment is 
completely offset by the reduction in air leaks and subsequent shorter hospital stay.
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OBJECTIVES: Therapeutic reference pricing (TRP) is one of the most frequently 
employed methods for cost-containment of pharmaceuticals. The Hungarian National 
Health Insurance Fund (NHIF) applies TRP based on DDD, yet even the WHO objects 
to using DDD in pricing and reimbursement decisions. Our objective was to compare 
actual drug use to DDD and to evaluate whether TRP based on DDD could result in 
savings in the costs of maintenance medication and the total direct health expenditures 
between asthma patients treated with Symbicort Turbuhaler (SYT) and Seretide Diskus 
(SED). METHODS: Real world data for the analysis was derived from the NHIF 
database. Actual drug use and average costs were compared in four groups (high dose 
SYT, medium dose SYT, high dose SED and medium dose SED). Multiple linear 
regression was employed to adjust data for the differences in gender and age distribu-
tion of patients. RESULTS: A total of 12,260 patients using SED and 15,539 patients 
using SYT for asthma were involved into the analysis. Average drug use was lower in 
both groups than DDD. Patients used 1.38–1.95 inhalations in both SED groups, 
1.28–1.97 inhalations in the high dose SYT group, and 1.74–2.49 inhalations in the 
medium dose SYT group. Although the daily therapeutic cost of medium dose SED 
based on DDD would be much lower than the cost of SYT, no difference was found 
in the actual cost of the maintenance therapy or the total medical costs. CONCLU-
SIONS: Our analysis provides evidence about the limitation of employing daily 
therapy costs according to DDD for TRP. No relationship was found between the 
daily therapeutic costs calculated using the NHIF methodology and costs of real drug 
use, in real world TRP did not lead to the reduction of expenditures from the payer’ 
perspective. Potential confounding factors may limit the generalizability of 
conclusions.
PRS17
COST OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A HEALTH 
CARE ADMINISTRATIVE DATABASES ANALYSIS
Fornari C1, Di Stasi F2, Blasi F3, Conti S1, Mantovani LG4, Merlino L5, Cesana G1
1University of Milano—Bicocca, Monza, MB, Italy; 2Nycomed S.p.a., Milan, MI, Italy; 3University 
of Milan—IRCCS Fondazione Ospedale Maggiore Policlinico Cà Granda, Milan, MI, Italy; 
4Federico II University of Naples, Naples, Italy; 5Regional Health Authority of Lombardy, 
Milan, MI, Italy
OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) currently represents 
the ﬁ fth leading cause of death worldwide and it’s estimated to rise to the third cause 
by 2030. Few studies have estimated the burden of COPD. The aim of this study was 
to evaluate consumption and cost of health care resources of severe COPD patients 
in the general population from the Italian health care system perspective. METHODS: 
Data were extracted from Healthcare Administrative Databases (HADs) of the region 
of Lombardy, which covers a population of 9.2 million members. HADs related to 
eligibility criteria, hospital admissions, pharmaceutical and outpatient claims have 
been organized in a data warehouse using probabilistic record linkage. The study 
included subjects aged more than 18 years that in 2003 had at least one hospitalization 
with COPD as the main diagnosis or as the second one when the main was: pneumo-
nia, respiratory or heart failure, pneumothorax and acute pulmonary heart disease. 
Subjects were followed for two years collecting information on health care resource 
and vital status. Severe and moderate exacerbations of COPD were respectively 
deﬁ ned as hospitalizations for COPD and as prescriptions of corticosteroids and/or 
antibiotics after the index hospitalization. RESULTS: We selected 16,476 patients 
with age mean 76 years and an average follow-up of 19 months. The 38% of patients 
were women with mean age three years higher than men. Subjects with severe exac-
erbations had on average 4.4 moderate and 1.9 severe episodes after the index hospi-
talization. The mean annual cost for these patients was c11,824 (IC95% 
11,554–12,079). Patients with only moderate exacerbations had on average 3.9 mod-
erate exacerbations and the mean annual cost was c6413 (IC95% 6288–6549). Costs 
were steady in time. CONCLUSIONS: The burden of COPD is important both in 
frequency and cost; it requires an effort in programming new health services particu-
larly devoted to aging population.
PRS18
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OBJECTIVES: This analysis estimates the health care costs (hospitalizations and 
outpatient visits) due to respiratory and co-morbid diseases in a cohort of subjects 
with and without COPD in Sweden. METHODS: A cohort of individuals was identi-
ﬁ ed in earlier clinical examinations of the general population within the Obstructive 
Lung Disease in Northern Sweden (OLIN) Studies. The cohort consisted initially of 
993 subjects fulﬁ lling criteria (GOLD) for COPD and an age- and gender matched 
control group of same size without obstructive lung function impairment. Since 2005, 
these subjects have been invited to yearly interviews and examinations. The participa-
tion rate has been high, above 85%. This analysis is based on resource use data col-
lected in 2006 (n = 772 COPD, n = 802 non-COPD). Unit costs from the Northern 
health care region price list of 2010 were used. RESULTS: The mean health care costs 
of all diseases amounted to c1421 (median c236) annually per subject with COPD 
compared to c1127 (median c169) for subjects without COPD (p = 0.16, non-
parametric Mann-Whitney). The mean costs in relation to disease severity were 
(GOLD criteria severity stage; p-value COPD vs. non-COPD): c1166 (mild; p = 0.66), 
c1755 (moderate; p = 0.28), c2223 (severe+very severe; P < 0.01). a minor part of the 
costs was attributable to respiratory diseases; 5.8% in non-COPD subjects and 10.5% 
in subjects with COPD. Respiratory disease costs were statistically signiﬁ cantly higher 
among subjects with COPD in all disease severity stages. CONCLUSIONS: The mean 
annual health care costs were c294 (median c67) higher for subjects with COPD. The 
difference in costs between subjects with severe+very severe COPD and subjects 
without the disease was statistically signiﬁ cant.
